Joe Sanderson
About Joe Sanderson
Joe Sanderson serves as the Head of Preclinical Safety at Adaptimmune, where he has worked since 2019. He has extensive experience in cancer immunotherapy and has held various roles within Adaptimmune, contributing to his expertise in scientific writing and people management.
Work at Adaptimmune
Joe Sanderson has been serving as the Head of Preclinical Safety at Adaptimmune since 2019. In this role, he oversees the safety assessments of preclinical studies, ensuring that the company's immunotherapy products are developed with a focus on safety and efficacy. Prior to this position, he held various roles at Adaptimmune, including Group Lead from 2016 to 2019, Senior Scientist from 2014 to 2016, and Scientist from 2012 to 2014. His tenure at Adaptimmune spans over a decade, contributing significantly to the company's research and development efforts in cancer immunotherapy.
Education and Expertise
Joe Sanderson earned his Doctor of Philosophy (PhD) in Pharmacology and Therapeutics from the University of Liverpool, completing his studies from 1997 to 2007. His academic background laid the foundation for his expertise in cancer immunotherapy, where he focuses on developing treatments that leverage the body's immune system to combat cancer. Additionally, he possesses specialized skills in Flow Cytometry, a critical technique in the analysis of cell populations, which supports his work in preclinical safety and research.
Background
Before joining Adaptimmune, Joe Sanderson worked as a Postdoctoral Research Fellow at the University of Southampton from 2008 to 2012. This role allowed him to further develop his research skills and deepen his understanding of cancer biology and immunotherapy. His career in the biotechnology industry has been marked by a progressive increase in responsibility, leading to his current position where he manages preclinical safety assessments.
Achievements
Throughout his career, Joe Sanderson has demonstrated strong skills in People Management, indicating his capability in leading and managing teams within the biotechnology sector. He also possesses significant experience in Scientific Writing, enabling him to effectively communicate complex scientific concepts and research findings. These skills contribute to his effectiveness in his current role and his overall impact in the field of cancer immunotherapy.